“…CS is a high-acuity, complex, and hemodynamically diverse state of end-organ hypoperfusion that is frequently associated with multivessel disease, which is more frequently followed by a worse outcome and mortality than single-vessel disease. The current American College of Cardiology/American Heart Association (ACC/AHA) and ESC guidelines do not recommend PCI of non-IRA at the time of primary PCI during acute myocardial infarction in patients with CS (class III, level of evidence B) because of the higher risk of death or renal failure [ 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 ]. Risks associated with CR include volume overload, contrast renal injury, more prolonged procedure times, and ischemic complications in the non-culprit vessel, resulting in further hemodynamic deterioration.…”